Lakhmir Chawla

Dr. Chawla is currently the Chief Medical Officer of Silver Creek Pharmaceuticals and previously was CMO at La Jolla Pharmaceutical Company (LJPC). Prior to joining LJPC, Dr. Chawla was a Professor of Medicine at George Washington University, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine as well as in the Department of Medicine, Division of Renal Diseases and Hypertension.

Dr. Chawla was previously the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. During his tenure at George Washington, Dr. Chawla was the designer and lead investigator of a pilot study called the ATHOS (Angiotensin II for the Treatment of High Output Shock) trial. This initial study was the first RCT of angiotensin II in shock and led to the initiation of La Jolla’s ATHOS 3 trial, a Phase 3 clinical trial of LJPC-501, which assessed angiotensin II for the treatment of catecholamine-resistant hypotension (shock). The ATHOS-3 Trial was published in the New England Journal of Medicine in 2017 and helped support the FDA approval of GIAPREZA (angiotensin II) in December 2017 and EMA approval in August 2019. Thereafter, Dr. Chawla oversaw the Medical Affairs launch and commercialization of GIAPREZA.

Dr. Chawla is an internationally renowned expert in the field of acute kidney injury (AKI), acute kidney disease (AKD), and shock. He remains an active investigator in the fields of AKI biomarkers, AKI risk prediction, AKI therapeutics, and chronic kidney disease caused by AKI.